|
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Conclusions The results support the use of the PHQ-9 and GAD-7 as brief, easy-to-use screening measures that can be administered by physicians to rapidly identify acute distress and inform treatment recommendations among TGNC youth seeking medical intervention.
|
30530884 |
2019 |
|
Depressive disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Hearing performance was assessed with Freiburg monosyllabic test and Oldenburg inventory (OI); the health-related quality of life was measured with Nijmegen Cochlear Implantation Questionnaire (NCIQ); depressive symptoms with General Depression Scale (ADS-L); stress with Perceived Stress Questionnaire (PSQ) and anxiety with General Anxiety Disorder-7 (GAD-7).
|
30870379 |
2019 |
|
Depressive disorder
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
There were a significant 58% increase of SCN GAD65/67-ir and a significant 169% increase of SCN GAD67-mRNA in the depression group.
|
28608287 |
2017 |
|
Depressive disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In a cross-sectional study, 23 patients with IPF were evaluated using Montreal Cognitive Assessment (MoCA), an instrument for detecting mild cognitive impairments and were screened for OSA through overnight cardiorespiratory polygraphy and for anxiety and depression with three specific scale (Generalized Anxiety Disorder 7-item scale: GAD-7; the Patient Health Questionnaire: PHQ-9; Hospital Anxiety and Depression Scale: HADS).
|
30707735 |
2019 |
|
Depressive disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Clinical diagnoses, the Patient Health Questionnaire depression (PHQ-9) and somatization modules (PHQ-15), the Generalized Anxiety Disorder Scale (GAD-7), the Liebowitz Social Anxiety Scale (LSAS), and the Short-Form-12 Health Survey (SF-12) were used in the clinical sample.
|
29178857 |
2017 |
|
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Changes in DEMS correlated with changes in both PHQ-8 and GAD-7 in the subgroup of patients without prior depression or anxiety diagnosis (ρ = 0.6, P = 0.002; ρ = 0.4, P = 0.02).
|
30950896 |
2019 |
|
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Depression was more commonly studied (ranged from 1%-30%).Prevalence of GAD ranged from 1%-26%.
|
29966886 |
2018 |
|
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
The PHQ-9 and GAD-7 were determined to be potential screening tools to aid Chinese medical workers in recognizing depression and anxiety in nonpsychiatric departments.
|
30762438 |
2019 |
|
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
This hypothesis is supported by a higher rate of suicide among male Test cricketers when compared with the UK male general population.<sup>1</sup> METHODS: This study ascertained rates of anxiety and depression by screening professional cricket players using the Generalised Anxiety Disorder Questionnaire (GAD-7) and Patient Health Questionnaire (PHQ-9).
|
28490460 |
2017 |
|
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Clinical correlates of FoP were assessed via a variety of measures, including patients' physical state (Karnofsky Performance Status, KPS), cancer-related psychosocial distress (Distress Thermometer, DT), anxiety (General Anxiety Disorder Scale, GAD-7), depression (Patient Health Questionnaire, PHQ-9), Quality of Life (Short Form Health Survey, SF-8), and unmet supportive care needs (Supportive Care Needs Survey, SCNS).
|
30684045 |
2019 |
|
Depressive disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In the third trimester, a second FOBS score, and saliva sample were collected, and the Personal Health Questionnaire-9 (PHQ-9) and General Anxiety Disorder-7 (GAD-7) were administered to measure depression and anxiety respectively.
|
31306998 |
2019 |
|
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Respectively 21.4% and 7.8% of the participants had depression and clinical symptoms of GAD.
|
30550597 |
2018 |
|
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
The GAD67-mediated depression became stable after 14 weeks.
|
30788386 |
2019 |
|
Depressive disorder
|
0.400 |
Biomarker
|
disease |
PSYGENET |
We also found suggestive associations in women for GAD1, GRIA3, and BDNF with depression accompanied by fatigue, and for CRHR1 with depression accompanied by early morning awakenings.
|
19548263 |
2010 |
|
Depressive disorder
|
0.400 |
Biomarker
|
disease |
PSYGENET |
In a recent association study in depression, which is highly comorbid with panic disorder, GAD1 risk allele associations were restricted to females.
|
22662185 |
2012 |
|
Depressive disorder
|
0.400 |
Biomarker
|
disease |
PSYGENET |
FMR1 gene polymorphisms, dopaminergic (DAT, DRD, COMT), serotonin (5-HTTLPR, HTR1A, HTR2A), interleukins, MCR1, HCN (potassium channel), neurorregulinas, GABAergic (GABA, GAD, DBI) DBI, GABA (Gabra) receptors and GAD genes (GAD1, GAD2) appear to contribute to generate condition of depression or anxiety like.
|
25106036 |
2014 |
|
Depressive disorder
|
0.400 |
Biomarker
|
disease |
PSYGENET |
As a consequence broader entities such as depression-GAD spectrum, panic-phobias spectrum and OCD spectrum including eating disorders and pathological gambling are taken into consideration; (c) Diagnostic categories use thresholds to delimitate a border with normals.This creates "subthreshold" conditions.
|
18344044 |
2008 |